DSGN
Design Therapeutics Inc

391
Mkt Cap
$635.84M
Volume
394,353.00
52W High
$11.23
52W Low
$2.60
PE Ratio
-8.46
DSGN Fundamentals
Price
$10.31
Prev Close
$10.26
Open
$10.26
50D MA
$10.15
Beta
1.63
Avg. Volume
197,070.73
EPS (Annual)
-$1.22
P/B
2.93
Rev/Employee
$0.00
$319.45
Loading...
Loading...
News
all
press releases
Design Therapeutics (NASDAQ:DSGN) Sets New 1-Year High - Here's Why
Design Therapeutics (NASDAQ:DSGN) Hits New 52-Week High - What's Next...
MarketBeat·4d ago
News Placeholder
More News
News Placeholder
Design Therapeutics (NASDAQ:DSGN) Sees Unusually-High Trading Volume - Time to Buy?
Design Therapeutics (NASDAQ:DSGN) Sees Large Volume Increase - Should You Buy...
MarketBeat·5d ago
News Placeholder
Design Therapeutics (NASDAQ:DSGN) Now Covered by Jefferies Financial Group
Jefferies Financial Group started coverage on Design Therapeutics in a research note on Monday. They set a "buy" rating and a $15.00 price target on the stock...
MarketBeat·5d ago
News Placeholder
Design Therapeutics Maps H2 Data Readouts for RESTORE-FA, FECD Biomarker Study and DM1 Program
Design Therapeutics (NASDAQ:DSGN) outlined its near-term clinical priorities and key upcoming data readouts during a conference discussion with Leerink Partners' Joe Schwartz, featuring comments from...
MarketBeat·6d ago
News Placeholder
Design Therapeutics, Inc. (NASDAQ:DSGN) Given Average Recommendation of "Moderate Buy" by Brokerages
Shares of Design Therapeutics, Inc. (NASDAQ:DSGN - Get Free Report) have earned a consensus rating of "Moderate Buy" from the five brokerages that are presently covering the company, MarketBeat.com...
MarketBeat·7d ago
News Placeholder
Design Therapeutics (NASDAQ:DSGN) Stock Price Up 6.7% After Analyst Upgrade
Design Therapeutics (NASDAQ:DSGN) Shares Up 6.7% on Analyst Upgrade...
MarketBeat·10d ago
News Placeholder
Royal Bank Of Canada Forecasts Strong Price Appreciation for Design Therapeutics (NASDAQ:DSGN) Stock
Royal Bank Of Canada raised their price objective on shares of Design Therapeutics from $13.00 to $14.00 and gave the company an "outperform" rating in a research note on Tuesday...
MarketBeat·11d ago
News Placeholder
Design Therapeutics (NASDAQ:DSGN) Posts Quarterly Earnings Results, Beats Expectations By $0.10 EPS
Design Therapeutics (NASDAQ:DSGN - Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.27) earnings per share for the quarter, beating analysts' consensus...
MarketBeat·12d ago
News Placeholder
Design Therapeutics (DSGN) Expected to Announce Quarterly Earnings on Monday
Design Therapeutics (NASDAQ:DSGN) will be releasing its Q4 2025 earnings before the market opens on Monday, March 9. (View Earnings Report at...
MarketBeat·19d ago
News Placeholder
Design Therapeutics Highlights GeneTAC Pipeline, FA Data Timeline and DM1 Dosing Plans at Oppenheimer Conference
Design Therapeutics (NASDAQ:DSGN) outlined progress across three clinical-stage programs and discussed upcoming catalysts during an Oppenheimer healthcare conference presentation led by CEO Pratik...
MarketBeat·23d ago
<
1
2
...
>

Latest DSGN News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.